Monday, June 15, 2026

The Next Trillion-Dollar Bet: Korean Pharma Invests in Immuno-Oncology, Targeting a $1 Trillion Global Market

Cho Yong-joon outlines Dongkoo Bio's transformation into a global healthcare leader, emphasizing convergence and innovative growth strategies.

DDM Immune Prep Delivers 100% Survival Against Drug-Resistant Bacteria and Flu in Pre-Exposure Tests

Researchers develop a novel infection-prevention strategy using DDM, enhancing immune response against antibiotic-resistant pathogens.

Tag: Johnson & Johnson

Yuhan’s Leclaza and J&J’s Rybrevant: How This Cancer Combo Surged Past 1 Billion USD in Sales

Sales of Yuhan's lung cancer drug 'Lazertinib' and J&J's 'Amivantamab' exceeded 1 trillion won last year.

Top News

- Our Sponsors Ad -

Follow us